Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1998 Sep 1;102(5):1035–1040. doi: 10.1172/JCI2773

The route of estrogen replacement therapy confers divergent effects on substrate oxidation and body composition in postmenopausal women.

A J O'Sullivan 1, L J Crampton 1, J Freund 1, K K Ho 1
PMCID: PMC508969  PMID: 9727072

Abstract

The route of estrogen replacement therapy has a major impact on the growth hormone (GH)/insulin-like growth factor-I (IGF-I) axis. Estrogen administration by the oral, but not the transdermal route, reduces IGF-I and increases GH levels in postmenopausal women. To investigate whether these perturbations have metabolic consequences, we compared the effects of 24 wk each of oral (Premarin 1.25 mg) and transdermal (Estraderm 100TTS) estrogen on energy metabolism and body composition in 18 postmenopausal women in an open-label randomized crossover study. Energy expenditure, lipid oxidation (lipid(ox)), and carbohydrate oxidation (CHOox) were measured by indirect calorimetry in the fasted and fed state before and after 2 and 6 mon treatment. Lean body mass, fat mass, and total body bone mineral density were measured by dual X-ray absorptiometry before and after 6 mon treatment. Mean (+/-SE) Luteinizing hormone levels fell to comparable levels during oral and transdermal estrogen, and bone mineral density was significantly increased by both treatments. Mean IGF-I was significantly lower during oral estrogen (77+/-7 versus 97+/-7 microg/liter, P < 0.05) treatment. Lipid(ox) 30-60 min after a standardized meal was significantly lower (36+/-5 versus 54+/-5 mg/min, P < 0.01) and CHOox higher (147+/-13 versus 109+/-12 mg/min, P < 0.05) with oral compared with transdermal estrogen. Oral estrogen resulted in a 1.2+/-0.5 kg (P < 0.05) increase in fat mass and a 1.2+/-0.4 kg (P < 0.01) decrease in lean mass compared with transdermal estrogen. Lean body mass (0.4+/-0.2 kg) and fat mass (0. 1+/-0.4 kg) did not change significantly during transdermal estrogen. In summary, when compared with the transdermal route, oral estrogen reduces lipid(ox), increases fat mass, and reduces lean body mass. The route of estrogen therapy confers distinct and divergent effects on substrate oxidation and body composition. The suppression of lipidox during oral estrogen therapy may increase fat mass although the fall in IGF-I may lead to a loss of lean body mass. The route-dependent changes in body composition observed during estrogen replacement therapy may have important implications for postmenopausal health.

Full Text

The Full Text of this article is available as a PDF (166.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barrett-Connor E. Postmenopausal estrogen and prevention bias. Ann Intern Med. 1991 Sep 15;115(6):455–456. doi: 10.7326/0003-4819-115-6-455. [DOI] [PubMed] [Google Scholar]
  2. Barrett-Connor E., Wingard D. L., Criqui M. H. Postmenopausal estrogen use and heart disease risk factors in the 1980s. Rancho Bernardo, Calif, revisited. JAMA. 1989 Apr 14;261(14):2095–2100. [PubMed] [Google Scholar]
  3. Baxter R. C., Brown A. S., Turtle J. R. Radioimmunoassay for somatomedin C: comparison with radioreceptor assay in patients with growth-hormone disorders, hypothyroidism, and renal failure. Clin Chem. 1982 Mar;28(3):488–495. [PubMed] [Google Scholar]
  4. Chetkowski R. J., Meldrum D. R., Steingold K. A., Randle D., Lu J. K., Eggena P., Hershman J. M., Alkjaersig N. K., Fletcher A. P., Judd H. L. Biologic effects of transdermal estradiol. N Engl J Med. 1986 Jun 19;314(25):1615–1620. doi: 10.1056/NEJM198606193142505. [DOI] [PubMed] [Google Scholar]
  5. Ferrannini E. The theoretical bases of indirect calorimetry: a review. Metabolism. 1988 Mar;37(3):287–301. doi: 10.1016/0026-0495(88)90110-2. [DOI] [PubMed] [Google Scholar]
  6. Forbes G. B., Reina J. C. Adult lean body mass declines with age: some longitudinal observations. Metabolism. 1970 Sep;19(9):653–663. doi: 10.1016/0026-0495(70)90062-4. [DOI] [PubMed] [Google Scholar]
  7. GRIZZLE J. E. THE TWO-PERIOD CHANGE-OVER DESIGN AN ITS USE IN CLINICAL TRIALS. Biometrics. 1965 Jun;21:467–480. [PubMed] [Google Scholar]
  8. Goldman L., Tosteson A. N. Uncertainty about postmenopausal estrogen. Time for action, not debate. N Engl J Med. 1991 Sep 12;325(11):800–802. doi: 10.1056/NEJM199109123251108. [DOI] [PubMed] [Google Scholar]
  9. Goldzieher J. W., Moses L. E., Averkin E., Scheel C., Taber B. Z. A placebo-controlled double-blind crossover investigation of the side effects attributed to oral contraceptives. Fertil Steril. 1971 Sep;22(9):609–623. [PubMed] [Google Scholar]
  10. Ho K. Y., Weissberger A. J., Marbach P., Lazarus L. Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly. Effects of dose and frequency and long-term safety. Ann Intern Med. 1990 Feb 1;112(3):173–181. doi: 10.7326/0003-4819-112-3-173. [DOI] [PubMed] [Google Scholar]
  11. Hoffman D. M., O'Sullivan A. J., Freund J., Ho K. K. Adults with growth hormone deficiency have abnormal body composition but normal energy metabolism. J Clin Endocrinol Metab. 1995 Jan;80(1):72–77. doi: 10.1210/jcem.80.1.7829643. [DOI] [PubMed] [Google Scholar]
  12. Hussain M. A., Schmitz O., Mengel A., Glatz Y., Christiansen J. S., Zapf J., Froesch E. R. Comparison of the effects of growth hormone and insulin-like growth factor I on substrate oxidation and on insulin sensitivity in growth hormone-deficient humans. J Clin Invest. 1994 Sep;94(3):1126–1133. doi: 10.1172/JCI117427. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Jørgensen J. O., Pedersen S. A., Thuesen L., Jørgensen J., Ingemann-Hansen T., Skakkebaek N. E., Christiansen J. S. Beneficial effects of growth hormone treatment in GH-deficient adults. Lancet. 1989 Jun 3;1(8649):1221–1225. doi: 10.1016/s0140-6736(89)92328-3. [DOI] [PubMed] [Google Scholar]
  14. Kelly J. J., Rajkovic I. A., O'Sullivan A. J., Sernia C., Ho K. K. Effects of different oral oestrogen formulations on insulin-like growth factor-I, growth hormone and growth hormone binding protein in post-menopausal women. Clin Endocrinol (Oxf) 1993 Nov;39(5):561–567. doi: 10.1111/j.1365-2265.1993.tb02410.x. [DOI] [PubMed] [Google Scholar]
  15. Lim L., Spencer S. A., McKay P., Waters M. J. Regulation of growth hormone (GH) bioactivity by a recombinant human GH-binding protein. Endocrinology. 1990 Sep;127(3):1287–1291. doi: 10.1210/endo-127-3-1287. [DOI] [PubMed] [Google Scholar]
  16. Mannor D. A., Winer L. M., Shaw M. A., Baumann G. Plasma growth hormone (GH)-binding proteins: effect on GH binding to receptors and GH action. J Clin Endocrinol Metab. 1991 Jul;73(1):30–34. doi: 10.1210/jcem-73-1-30. [DOI] [PubMed] [Google Scholar]
  17. Manolio T. A., Furberg C. D., Shemanski L., Psaty B. M., O'Leary D. H., Tracy R. P., Bush T. L. Associations of postmenopausal estrogen use with cardiovascular disease and its risk factors in older women. The CHS Collaborative Research Group. Circulation. 1993 Nov;88(5 Pt 1):2163–2171. doi: 10.1161/01.cir.88.5.2163. [DOI] [PubMed] [Google Scholar]
  18. Mauras N., Beaufrere B. Recombinant human insulin-like growth factor-I enhances whole body protein anabolism and significantly diminishes the protein catabolic effects of prednisone in humans without a diabetogenic effect. J Clin Endocrinol Metab. 1995 Mar;80(3):869–874. doi: 10.1210/jcem.80.3.7533772. [DOI] [PubMed] [Google Scholar]
  19. Møller J., Jørgensen J. O., Møller N., Christiansen J. S., Weeke J. Effects of growth hormone administration on fuel oxidation and thyroid function in normal man. Metabolism. 1992 Jul;41(7):728–731. doi: 10.1016/0026-0495(92)90312-x. [DOI] [PubMed] [Google Scholar]
  20. Møller N., Jørgensen J. O., Alberti K. G., Flyvbjerg A., Schmitz O. Short-term effects of growth hormone on fuel oxidation and regional substrate metabolism in normal man. J Clin Endocrinol Metab. 1990 Apr;70(4):1179–1186. doi: 10.1210/jcem-70-4-1179. [DOI] [PubMed] [Google Scholar]
  21. Nabulsi A. A., Folsom A. R., White A., Patsch W., Heiss G., Wu K. K., Szklo M. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. The Atherosclerosis Risk in Communities Study Investigators. N Engl J Med. 1993 Apr 15;328(15):1069–1075. doi: 10.1056/NEJM199304153281501. [DOI] [PubMed] [Google Scholar]
  22. O'Sullivan A. J., Ho K. K. A comparison of the effects of oral and transdermal estrogen replacement on insulin sensitivity in postmenopausal women. J Clin Endocrinol Metab. 1995 Jun;80(6):1783–1788. doi: 10.1210/jcem.80.6.7775623. [DOI] [PubMed] [Google Scholar]
  23. O'Sullivan A. J., Hoffman D. M., Ho K. K. Estrogen, lipid oxidation, and body fat. N Engl J Med. 1995 Sep 7;333(10):669–670. doi: 10.1056/NEJM199509073331018. [DOI] [PubMed] [Google Scholar]
  24. O'Sullivan A. J., Kelly J. J., Hoffman D. M., Baxter R. C., Ho K. K. Energy metabolism and substrate oxidation in acromegaly. J Clin Endocrinol Metab. 1995 Feb;80(2):486–491. doi: 10.1210/jcem.80.2.7852509. [DOI] [PubMed] [Google Scholar]
  25. O'Sullivan A. J., Kelly J. J., Hoffman D. M., Freund J., Ho K. K. Body composition and energy expenditure in acromegaly. J Clin Endocrinol Metab. 1994 Feb;78(2):381–386. doi: 10.1210/jcem.78.2.8106626. [DOI] [PubMed] [Google Scholar]
  26. Ockner R. K., Lysenko N., Manning J. A., Monroe S. E., Burnett D. A. Sex steroid modulation of fatty acid utilization and fatty acid binding protein concentration in rat liver. J Clin Invest. 1980 May;65(5):1013–1023. doi: 10.1172/JCI109753. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Posthuma W. F., Westendorp R. G., Vandenbroucke J. P. Cardioprotective effect of hormone replacement therapy in postmenopausal women: is the evidence biased? BMJ. 1994 May 14;308(6939):1268–1269. doi: 10.1136/bmj.308.6939.1268. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Postmenopausal estrogen use and heart disease. N Engl J Med. 1986 Jul 10;315(2):131–136. doi: 10.1056/NEJM198607103150213. [DOI] [PubMed] [Google Scholar]
  29. Powers M. S., Schenkel L., Darley P. E., Good W. R., Balestra J. C., Place V. A. Pharmacokinetics and pharmacodynamics of transdermal dosage forms of 17 beta-estradiol: comparison with conventional oral estrogens used for hormone replacement. Am J Obstet Gynecol. 1985 Aug 15;152(8):1099–1106. doi: 10.1016/0002-9378(85)90569-1. [DOI] [PubMed] [Google Scholar]
  30. Pratt W. F., Bachrach C. A. What do women use when they stop using the pill? Fam Plann Perspect. 1987 Nov-Dec;19(6):257–266. [PubMed] [Google Scholar]
  31. Pérez Gutthann S., García Rodríguez L. A., Castellsague J., Duque Oliart A. Hormone replacement therapy and risk of venous thromboembolism: population based case-control study. BMJ. 1997 Mar 15;314(7083):796–800. doi: 10.1136/bmj.314.7083.796. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Rudman D. Growth hormone, body composition, and aging. J Am Geriatr Soc. 1985 Nov;33(11):800–807. doi: 10.1111/j.1532-5415.1985.tb04195.x. [DOI] [PubMed] [Google Scholar]
  33. Salomon F., Cuneo R. C., Hesp R., Sönksen P. H. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med. 1989 Dec 28;321(26):1797–1803. doi: 10.1056/NEJM198912283212605. [DOI] [PubMed] [Google Scholar]
  34. Stampfer M. J., Colditz G. A., Willett W. C., Manson J. E., Rosner B., Speizer F. E., Hennekens C. H. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. N Engl J Med. 1991 Sep 12;325(11):756–762. doi: 10.1056/NEJM199109123251102. [DOI] [PubMed] [Google Scholar]
  35. Suter P. M., Schutz Y., Jequier E. The effect of ethanol on fat storage in healthy subjects. N Engl J Med. 1992 Apr 9;326(15):983–987. doi: 10.1056/NEJM199204093261503. [DOI] [PubMed] [Google Scholar]
  36. Walker J. L., Ginalska-Malinowska M., Romer T. E., Pucilowska J. B., Underwood L. E. Effects of the infusion of insulin-like growth factor I in a child with growth hormone insensitivity syndrome (Laron dwarfism). N Engl J Med. 1991 May 23;324(21):1483–1488. doi: 10.1056/NEJM199105233242107. [DOI] [PubMed] [Google Scholar]
  37. Walsh B. W., Schiff I., Rosner B., Greenberg L., Ravnikar V., Sacks F. M. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med. 1991 Oct 24;325(17):1196–1204. doi: 10.1056/NEJM199110243251702. [DOI] [PubMed] [Google Scholar]
  38. Weinstein I., Soler-Argilaga C., Werner H. V., Heimberg M. Effects of ethynyloestradiol on the metabolism of [1-14C]oleate by perfused livers and hepatocytes from female rats. Biochem J. 1979 May 15;180(2):265–271. doi: 10.1042/bj1800265. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Weissberger A. J., Ho K. K., Lazarus L. Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women. J Clin Endocrinol Metab. 1991 Feb;72(2):374–381. doi: 10.1210/jcem-72-2-374. [DOI] [PubMed] [Google Scholar]
  40. Zurlo F., Lillioja S., Esposito-Del Puente A., Nyomba B. L., Raz I., Saad M. F., Swinburn B. A., Knowler W. C., Bogardus C., Ravussin E. Low ratio of fat to carbohydrate oxidation as predictor of weight gain: study of 24-h RQ. Am J Physiol. 1990 Nov;259(5 Pt 1):E650–E657. doi: 10.1152/ajpendo.1990.259.5.E650. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES